Trevi Therapeutics (TRVI) Capital Expenditures (2018 - 2026)

Trevi Therapeutics' Capital Expenditures history runs 8 years deep, the most recent figure standing at $102000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $102000.0 in Q1 2026; TTM through Mar 2026 was $121000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $12000.0, down 65.71% from the prior year.
• Capital Expenditures rose to $102000.0 in Q1 2026 per TRVI's latest filing, from $12000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $116000.0 in Q4 2022 and bottomed at $7000.0 in Q4 2024.
• The 5-year median for Capital Expenditures is $31000.0 (2023), against an average of $46750.0.
• Across the five-year window, Capital Expenditures plunged 81.03% in 2023 and slumped 68.18% in 2024, its largest moves.
• Year by year, Capital Expenditures stood at $116000.0 in 2022, then plunged by 81.03% to $22000.0 in 2023, then sank by 68.18% to $7000.0 in 2024, then jumped by 71.43% to $12000.0 in 2025, then soared by 750.0% to $102000.0 in 2026.
• Per Business Quant, the three latest TRVI Capital Expenditures figures stand at $102000.0 (Q1 2026), $12000.0 (Q3 2025), and $7000.0 (Q4 2024).